Interim analysis of the German non-interventional post marketing surveillance study (NIS) on Quality of Life (QoL) of capecitabine in patients with metastatic breast cancer (MBC).

31. Mai 2010

Zaiss, M., Fuxius, S., Lerchenmueller, C., Hahn, L., Luhn, B., Marschner, N., Steffens, C.C., Soeling, U., Mueller, V., 2010.

Ann Oncol 21 (suppl 8)(314P), viii108. doi:10.1093/annonc/mdq517